{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:58:10Z","timestamp":1740142690437,"version":"3.37.3"},"reference-count":17,"publisher":"FapUNIFESP (SciELO)","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"DOI":"10.1590\/1806-9282.65.4.530","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T11:34:56Z","timestamp":1556883296000},"page":"530-534","source":"Crossref","is-referenced-by-count":0,"title":["Moderate to severe plaque psoriasis - treatment with drugs of the classic scheme"],"prefix":"10.1590","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-5161","authenticated-orcid":false,"given":"Marcelo","family":"Arnone","sequence":"first","affiliation":[{"name":"Brazilian Society of Urology,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0407-538X","authenticated-orcid":false,"given":"Andr\u00e9 Vicente Esteves de","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Brazilian Society of Urology,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8671-6680","authenticated-orcid":false,"given":"Maria Denise Fonseca","family":"Takahash\u00ed","sequence":"additional","affiliation":[{"name":"Brazilian Society of Urology,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-5207","authenticated-orcid":false,"given":"Wanderley M","family":"Bernardo","sequence":"additional","affiliation":[{"name":"Brazilian Medical Association,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2019,4]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat JH","year":"2008","journal-title":"Br J Dermatol."},{"issue":"10068","key":"ref2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","article-title":"An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Warren Richard B","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaad.2009.12.029","article-title":"Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial","volume":"63","author":"Reich K","year":"2010","journal-title":"J Am Acad Dermatol."},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1365-2230.2009.03693.x","article-title":"Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life","volume":"35","author":"Ho SG","year":"2010","journal-title":"Clin Exp Dermatol."},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1111\/j.1468-3083.2012.04644.x","article-title":"Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study","volume":"27","author":"Dogra S","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0190-9622(89)70138-9","article-title":"Side-effect profile of acitretin therapy in psoriasis","volume":"20","author":"Gupta AK","year":"1989","journal-title":"J Am Acad Dermatol."},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1177\/039463201002300418","article-title":"Psoriasis relapse evaluation with week-end cyclosporine A treatment: results of a randomized, double-blind, multicenter study","volume":"23","author":"Colombo D","year":"2010","journal-title":"Int J Immunopathol Pharmacol."},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2133.1994.tb02935.x","article-title":"Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis","volume":"130","author":"Laburte C","year":"1994","journal-title":"Br J Dermatol."},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/0190-9622(92)70012-5","article-title":"Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study","volume":"26","author":"Christophers E","year":"1992","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2133.2007.08236.x","article-title":"Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis","volume":"158","author":"Revicki D","year":"2008","journal-title":"Br J Dermatol."},{"issue":"5","key":"ref11","first-page":"554","article-title":"Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis","volume":"13","author":"Navarini AA","year":"2014","journal-title":"J Drugs Dermatol."},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker J","year":"2011","journal-title":"Br J Dermatol."},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10875-008-9233-0","article-title":"Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial","volume":"29","author":"Caproni M","year":"2009","journal-title":"J Clin Immunol."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad AR","year":"1996","journal-title":"Control Clin Trials"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jebm.12018","article-title":"Understanding GRADE: an introduction","volume":"6","author":"Goldet G","year":"2013","journal-title":"J Evid Based Med"},{"series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells G","key":"ref16"},{"series-title":"Levels of Evidence and Grades of Recommendations - Oxford Centre for Evidence Based Medicine","key":"ref17"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v65n4\/1806-9282-ramb-65-04-0530.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T13:07:29Z","timestamp":1581080849000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302019000400530&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4]]}},"alternative-id":["S0104-42302019000400530"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.65.4.530","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"type":"electronic","value":"1806-9282"},{"type":"print","value":"0104-4230"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}